ASCO: Celgene says blood cancer patients respond to Thalidomide
08 June, 2004 by Staff WritersThalidomide, a cause of severe birth defects in children in the 1950's, and currently approved for the treatment of leprosy, was found to be effective in a clinical trial for treating patients with multiple myeloma, a form of blood cancer.
Panbio nets grant, moves most manufacturing to Brisbane
08 June, 2004 by Graeme O'NeillMedical diagnostics company Panbio (ASX:PBO) has been awarded a Queensland government grant towards the cost of developing its new R&D and manufacturing facility in Brisbane.
Ambri system makes clinical debut
07 June, 2004 by Renate KrelleThe first diagnostic system to use an ion-channel switch, able to sense tiny concentrations of a specific molecule, has been installed in the pathology laboratory at Sydney's Royal North Shore Hospital.
Austin, Ludwig to run PII melanoma vaccine trial
07 June, 2004 by Melissa TrudingerThe Austin Health/Ludwig Institute of Cancer Research (LICR) joint oncology unit has received a grant of US$600,000 from US-based cancer charity, the Cancer Research Institute (CRI), to conduct an international Phase II clinical trial that will test the effectiveness of a therapeutic vaccine for melanoma.
EQiTX pain-soothing molecules show promise
04 June, 2004 by Graeme O'NeillResearch by a University of Queensland research team suggests Melbourne-based biotech ZingoTX may have a lead compound for neuropathic pain in its synthetic derivatives of the mouth-burning molecules found in ginger and chillies.
Bayer pulls plug on GM canola trial in NSW
04 June, 2004 by Graeme O'NeillAt the last minute, Agbiotech giant Bayer CropScience has pulled the plug on its plan to conduct a 40-hectare demonstration trial of its genetically modified hybrid canolas in NSW.
GTG to DNA-test 20,000 NZ sheep
04 June, 2004 by Graeme O'NeillMelbourne biotech Genetic Technologies (ASX:GTG) has signed its first contract with New Zealand agbiotech company Ovita in Dunedin for a pilot program to DNA-test up to 20,000 sheep.
Amrad stunned as Serono drops emfilermin trial
04 June, 2004 by Melissa TrudingerAmrad (ASX:AML) has been dealt a blow with the news that Serono is abandoning further development of emfilermin following Phase II clinical trial results that showed the molecule was no more efficacious than the placebo.
New biotech Bone revs up in Perth
03 June, 2004 by Renate KrelleA new biotechnology company sprang into being yesterday -- seemingly fully-formed -- when Perth-based Revenir (ASX:REV), formerly a property management company, announced plans to merge with private British biopharmaceutical company Bone Limited.
Prima subsidiary touts cancer antibody success
03 June, 2004 by Melissa TrudingerPrima Biomed (ASX:PRR) subsidiary Oncomab has published results of an animal study demonstrating the efficacy of its anti-Cripto monoclonal antibody in a mouse model of human colon cancer.
Solbec mesothelioma trial shows promise
03 June, 2004 by Graeme O'NeillThe news from a pre-clinical trial of Perth biopharma Solbec Pharmaceuticals' (ASX:SBP) lead anti-cancer compound SBO002 could hardly be more positive.
QLD 'kissing disease' vaccine on the way
02 June, 2004 by Graeme O'NeillResearchers at the Queensland Institute for Medical Research (QIMR) in Brisbane hope to begin human trials late this year of a vaccine that could prevent three different forms of cancer associated with infection by Epstein-Barr virus.
Cerylid, Kinacia to merge
02 June, 2004 by Melissa TrudingerMelbourne biotech Cerylid Biosciences has acquired fellow unlisted biotech Kinacia in a merger that finally puts an end to months of rumour.
Regenera closes oversubscribed in tough market
02 June, 2004 by Renate KrellePerth-based opthamology specialist Regenera has prevailed in an increasingly tough IPO market, closing its IPO today AUD$2 million oversubscribed, having raised in excess of AUD$10 million.
Psivida takes over UK subsidiary
02 June, 2004 by Graeme O'NeillPerth-based nano-biotech company Psivida (ASX:PSD) has acquired 100 per cent ownership of its UK subsidiary PsiMedica in a AUD$57.8 million deal aimed at accelerating development of its BioSilicon technology.
